The hdm-2 oncogene is overexpressed in several types of malignancies including osteosarcomas, soft tissue sarcomas and gliomas and hdm-2 has been associated with accelerated tumor formation in both hereditary and sporadic cancers. Among the other key binding partners, hdm-2 forms a complex with the tumor suppressor p53, resulting in a rapid proteasome-mediated degradation of the p53 protein. This positions the hdm-2-p53 complex as an attractive target for the development of anticancer therapy and recently the first small molecule hdm-2 antagonist has been reported. Development of hdm-2 antagonists is currently focused on malignancies containing a wild-type p53 genotype, which is the case in approximately half of human cancer indications. However, hdm-2 has also been implicated in oncogenesis in the absence of p53. We therefore studied the effect of hdm-2 antagonists in p53-deficient human H1299 lung carcinoma cells. The hdm-2 antagonistic peptide caused G1 cell cycle arrest, inhibited colony growth and induced expression of G1 checkpoint regulatory proteins, such as p21 waf1, cip1 . These data demonstrate that hdm-2 regulates the G1 cell cycle checkpoint in a p53-independent manner, suggesting that hdm-2 antagonists represent a novel class of anticancer therapeutics with broad applicability towards tumors with different p53 genetic backgrounds.
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The mouse double-minute-2 (mdm-2) gene and its human homolog hdm-2 are potent oncogenes as demonstrated by their capacity to induce tumor formation when overexpressed in nude mice (Fakharzadeh et al., 1993) . Hdm-2 is overexpressed in several types of malignancies including osteosarcomas, soft tissue sarcomas and gliomas, and high levels of hdm-2 are associated with poor prognosis (Cordon-Cardo et al., 1994) . Recently, a single nucleotide polymorphism in the hdm-2 promoter (SNP309), which increases hdm-2 expression, was associated with accelerated tumor formation in both hereditary and sporadic cancers (Bond et al., 2004) . The oncogenic capacity of hdm-2 has been linked to its key role in regulating expression of the tumor suppressor p53 (Momand and Zambetti, 1997) . Hdm-2 binds and ubiquitinates the p53 protein, which results in a rapid degradation of p53 by the proteasome (Bottger et al., 1997a) . Abrogation of the hdm-2-p53 complex causes p53 stabilization and subsequent transcription of p53 downstream genes resulting in cell cycle arrest and apoptosis (Lane, 1992) .
The hdm-2-p53 interaction domain has been co-crystallized revealing that the N-terminal region of hdm-2 forms a deep hydrophobic cleft in which three p53 amino-acid residues, namely Phe19, Trp23 and Leu26, deeply insert into (Kussie et al., 1996) . Small peptides or antibodies directed against the hdm-2 cleft block the interaction, resulting in p53 induction and cell cycle arrest (Bottger et al., 1997b; Blaydes et al., 1997) . Based on its structure, the hdm-2/p53 interface has been predicted to be amenable for small molecule proteinprotein interaction inhibitors (Fischer and Lane, 2004) . Recently, the first small molecule antagonist of the hdm-2 pocket (Nutlin) was described by Vassilev et al. (2004) . Nutlin stabilizes p53, inhibits tumor cell proliferation and shows in vivo antitumor activity. These results further demonstrate the attractiveness of hdm-2 antagonists as therapeutic agents. Development of hdm-2 antagonists is currently focused on malignancies containing the wild-type p53 genotype, which is the case in half of the human cancer patients (Hollstein et al., 1991) . Interestingly however, hdm-2 has also been implicated in oncogenesis in the absence of p53. Overexpression of the hdm-2 gene in p53-deficient mice induces spontaneous formation of sarcomas (Jones et al., 1998) . So far however, the mechanism through which hdm-2 exerts its oncogenic properties in the absence of p53 is still largely unknown. The N-terminal domain of hdm-2 has been described to interact with a number of additional cell cycle regulatory proteins such as the S phase transcription factor E2F1-DP1. Hdm-2-E2F1 interaction results in an increased transcription of S phase promoting genes (Martin et al., 1995) . Furthermore, antagonists of the hdm-2 pocket induce E2F1 protein expression demonstrating that the Nterminal domain of hdm-2 is a key regulator for the activity of this transcription factor (Blattner et al., 1999) . In addition to E2F1, the N-terminal domain of hdm-2 has also been found to stabilize the p53 homolog p73. The interaction of p73 with hdm-2 antagonizes the transcriptional activity of p73 (Dobbelstein et al., 1999) . The observation that a number of different cell cycle regulators interact with hdm2, suggests that therapeutic agents interfering with the hdm-2 hydrophobic cleft might also affect the growth of p53-mutant tumors. To get more insight into the mechanism by which hdm-2 controls tumor cell proliferation in the absence of p53, we used small peptide antagonists binding into the hydrophobic cleft of hdm-2. These peptides have previously been shown to inhibit p53-hdm-2 interaction, induce p53 accumulation and subsequent cell cycle arrest (Bottger et al., 1997b) . We have expressed the hdm-2 antagonistic peptide (HAP) as a fusion protein with enhanced green fluorescent protein (EGFP) to visualize peptide expression. A construct encoding EGFP alone (control) and a mutant peptide fused to EGFP (HAP-Ala) were used as negative controls. For the mutant peptide, three key binding amino-acid residues (Phe19, Trp23 and Leu26) were mutated into alanine resulting in an inactive peptide (Bottger et al., 1997b) . We selected p53 wild-type human A2780 ovarian carcinoma cells, p53 mutant C33A cervix carcinoma cells and p53-deficient H1299 non-small-cell lung carcinoma cells to evaluate the role of p53 in the effect of hdm-2 antagonism. As shown in Figure 1a , transient transfection of the control constructs resulted in high fluorescence after 48 h for all three cell lines. In contrast, only low fluorescence was observed when HAP was expressed. These data suggest that high expression of the hdm-2 antagonist peptide is not well tolerated either in the presence or absence of p53. In order to investigate the kinetics of this effect, we constructed a system that allowed a stable constitutive expression of the peptide. Figure 1b shows the fluorescence intensity profiles of the peptides after stable constitutive expression in A2780, C33A and H1299 cells. A high fluorescence was observed for A2780, C33A and H1299 cells expressing the control vector, showing that (Swift et al., 1999) . Infected cells were cultured under doxycyclin suppression (200 ng/ml), and subsequenly doxycyclin was removed for 2 days in order to induce HAP expression under control of the tet-responsive element (TRE) (Swift et al., 1999 , Lorens et al., 2000 . Fluorescence-activated cell sorting analysis on a high-speed sorting apparatus (MoFlow, Cytomation Inc., CO, USA) was used to visualize HAP and HAP-Ala expression levels. Data shown are representative for three independent experiments. p53-Independent antitumor effect of an hdm2 antagonist A VanderBorght et al EGFP was not inducing any toxicity in the cell lines tested. Also for the HAP-Ala population, fluorescence was relatively high. For the HAP-expressing cells on the other hand, a remarkable reduction in the mean fluorescence was observed after 2 days of expression. This decrease in mean fluorescence was due to the absence of high expressing cells and was also observed in p53-deficient H1299 cells showing that this effect was independent of the p53 genotype.
In order to study a potential effect on tumor cell proliferation in a p53-deficient background, cell cycle analysis was performed on H1299 cells after regulated p53-Independent antitumor effect of an hdm2 antagonist A VanderBorght et al induction of HAP. A pure population of HAP-expressing H1299 cells was obtained by cell sorting and cultured in the presence or absence of doxycyclin in order to regulate peptide expression. As shown in Figure 2a , removal of doxycyclin resulted in an induction of peptide expression, whereas in the presence of doxycyclin complete suppression was observed. Next, cell cycle analysis showed an increase in G0/G1 phase cells (from 52 to 61%) after 8 days of HAP induction, which was paralleled by a reduction in the percentage of cells in S phase (from 33 to 25%). This G0/G1 arrest was found on days 4 and 8, but not on day 2 after induction.
No effect on the percentage of G2M phase cells was found. Also, no cell death was observed, as evident from the absence of a sub-G1 population for HAP-expressing H1299 cells (Figure 2a) . Although the extent of G1 cell cycle arrest observed is relatively small, the effect was very reproducible across experiments for all time points (Figure 2b ). In addition, it should be noted that in order to obtain a pure population, HAP expression was induced for 2 days before cell sorting was performed.
As fluorescence of the sorted HAP population was significantly lower as in the HAP-Ala and control cells (Figure 1 ), high HAP-expressing cells may have been lost during this induction phase. As a consequence, the antiproliferative effects observed with the hdm-2 antagonist may be significantly underestimated. In order to investigate whether the cell cycle arrest caused by the hdm-2 antagonist peptide in H1299 cells resulted in an effect on tumor cell growth, a colony formation assay was performed. No effect was found on colony number (data not shown). HAP expression however, showed significant growth inhibition when subsequently analyzing colony size. As shown in Figure 2c , the percentage of large colonies (69716) is significantly lower when HAP is induced as compared to the corresponding suppressed population (124719). This is paralleled by a significant increase in the percentage of small colonies for the HAP-induced (119715, Po0.05) as compared to the HAP-suppressed cells (9576). For the HAP-Ala cells, on the other hand, no effect on colony size was observed after HAP-Ala induction. The observed overall decreased number of large colonies formed in the HAP-Ala-infected population is not related to the expression of the mutant peptide, as this was also observed under suppressed conditions. Based on these data, we conclude that expression of an antagonist peptide blocking the hdm-2 pocket inhibits the proliferation of the p53-deficient H1299 lung carcinoma cells.
In order to clarify how hdm-2 antagonists inhibit tumor cell proliferation and induce G0/G1 cell cycle arrest in the absence of p53, we subsequently studied key players involved in G1 checkpoint regulation, such as the cyclin-dependent kinase inhibitors p21 waf1,cip1 and p16. Cyclin-dependent kinase inhibition prevents phosphorylation of the retinoblastoma (Rb)/E2F1 complex, resulting in a G1 cell cycle arrest. As shown in Figure 3 , the induction of HAP at 24 h was paralleled by an increase of p21 waf1,cip1 and, to a lesser extent, p16 protein expression which was still evident at 48 and at 72 h. The p21 waf1,cip1 induction at 24 h is rather quick, taking into account that a clear G1 arrest was observed after 4 days (Figure 2b ). The modest increase in p21 waf1,cip1 under suppressed conditions correlates with a minor leakage of the HAP protein at 48 and 72 h. For the HAP-Ala control group, no effect on G1 checkpoint proteins upon expression of the peptide was observed. We also found an induction of the Rb protein expression and as a result the phosphorylated Rb (pRb) at all time points in HAP-expressing cells. In agreement with our observation, recently Sdek et al. (2005) published that Hdm2 promotes proteasome-dependent ubiquitin-independent degradation of the Rb protein. In their study, Hdm2 ablation resulted in Rb accumulation and inhibition of DNA synthesis. Our data suggest that antagonists of the N-terminal Hdm2 domain have similar effects.
To further confirm the p53-independent regulation of cell cycle progression through the Hdm2 N-terminal domain, we subsequently studied the effect of Nutlin-3. Similar to HAP, Nutlin-3 also selectively binds the Hdm2 N-terminal pocket, which has been validated by co-crystallization experiments (Vassilev et al., 2004) . As shown in Figure 4 , indeed Nutlin-3 also induced p21 waf1,cip1 and G1 cell cycle arrest, thereby further validating the specificity of the effects we observed in our studies with HAP.
Several publications may explain how p21
protein levels are regulated by hdm-2 in a p53 null Figure 2 HAP inhibits cell cycle progression and colony growth of p53-deficient H1299 cells. H1299 (p53-deficient) non-small-cell lung carcinoma cells stably expressing HAP, HAP-Ala and empty vector (control) were seeded in the absence (induced, I) and presence (supressed, S) of doxycyclin (200 ng/ml). (a and b) Cell cycle analysis was performed using propidium iodide staining according to Vindelov et al. (1983) , and analysis was performed using a FACScalibur (Becton Dickinson, San Jose, CA, USA). Cell cycle profiles were analysed using Modfit software (ModFit for Mac degradation by the proteasome was observed when hdm-2 binds to p21
. This hdm-2/proteosomemediated p21
waf1,cip1 degradation could be prevented by downregulating hdm-2 expression (Zhang et al., 2004) . It should be noted, however, that the proteosomemediated degradation of the p21/hdm-2 complex has not directly been associated to the hdm-2 N-terminal domain against which our hdm-2 antagonists were targeted. Alternatively, however, p21 waf1,cip1 induction by antagonists may also be caused by the stabilization of other proteins such as p73 known to bind to the N-terminus of hdm-2. p73 is known to be transcriptionally inactivated as a result of its hdm-2 interaction, and is a known transcriptional regulator of p21 waf1,cip1 (Jost et al., 1997; Dobbelstein et al., 1999) . The binding site of p73 on hdm-2 is the N-terminal hydrophobic cleft which is the domain targeted by the hdm-2 antagonist peptide as used in this study. Interestingly, we observed that Nutlin-3 induces p73 levels in p53-deficient H1299 cells (Figure 4 ). The N-terminal hydrophobic domain has also been found to interact with the transcription factor E2F1, a protein essential for S phase progression. E2F1 was found to contribute to the p53-independent oncogenic effects of hdm-2 as the interaction between hdm-2 and E2F1 was shown to stimulate E2F1 transcriptional activity in p53-deficient SAOS2 cells (Martin et al., 1995) . This would suggest that hdm-2 antagonists possibly antagonize E2F1 activity and thereby inhibit S phase progression. This is in agreement with our observations that the hdm-2 antagonist causes G1 cell cycle arrest, although we have not investigated E2F1 activity up to date.
In summary, our data show that hdm-2 plays a key role in inhibiting the G1 checkpoint, thereby supporting tumor proliferation in the absence of p53. These results suggest that therapeutics based on hdm-2 antagonism may have a broad applicability towards tumors with different p53 backgrounds. waf1,cip1 expression and G1 cell cycle arrest in p53-deficient H1299 lung carcinoma cells. H1299 nonsmall-cell lung carcinoma cells were incubated for 24 h with solvent (control) or Nutlin-3 at the indicated concentrations. (a) Total cell lysates were prepared in RIPA buffer and proteins were separated by SDS-PAGE. Protein expression was analysed by Western blotting using specific antibodies for p21 wafÀ1,cipÀ1 (BD Pharmingen) and p73 (Abcam, Cambridge, UK). Actin protein levels (Oncogene Research Products) were revealed as a control for equal loading. (b) H1299 cells were incubated with Nutlin 3 at 30 mM, and cell cycle analysis was performed after 24 h using using the Guava PCA-96 System. Figure 3 HAP induces G1 checkpoint-related proteins in p53-deficient H1299 lung carcinoma cells. H1299 cells were seeded in the absence and presence of doxycyclin, and harvested at the indicated time points. Total cell lysates were prepared in radio immunoprecipitation assay (RIPA) buffer and proteins were separated by Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Protein expression was analysed by Western blotting using specific antibodies for p21 wafÀ1,cipÀ1 (BD Pharmingen, Erembodegem, Belgium), p16 (BD Pharmingen), Rb (Cell Signalling Technology, Beverly, MA, USA), pRb_Ser780 (Cell Signalling Technology) and EGFP (Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Actin protein levels (Oncogene Research Products, San Diego, CA, USA) were revealed as a control for equal loading. Protein-antibody complexes were visualized by chemiluminescence (Super Signal West Dura reagent, Pierce Chemical, Carmlington, UK) and fluorescence (Odyssey, Li-Cor Biosciences, Lincoln, Nebraska) according to manufacturer's instructions.
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